PubRank

G Caleb Alexander

Author PubWeight™ 121.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lying to insurance companies: the desire to deceive among physicians and the public. Am J Bioeth 2004 8.49
2 Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008 5.27
3 The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med 2008 4.33
4 Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006 3.81
5 Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health 2009 3.13
6 National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012 2.27
7 The Food and Drug Administration Amendments Act and postmarketing commitments. JAMA 2013 2.27
8 Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010 2.05
9 National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005 2.01
10 Are Food and Drug Administration prescription drug safety plans working? A case study of isotretinoin. Pharmacoepidemiol Drug Saf 2013 1.97
11 The role of surgeon error in withdrawal of postoperative life support. Ann Surg 2012 1.97
12 The physician-surrogate relationship. Arch Intern Med 2007 1.93
13 Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care 2012 1.91
14 Substituted judgment: the limitations of autonomy in surrogate decision making. J Gen Intern Med 2008 1.88
15 The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health 2015 1.86
16 General internists' views on pay-for-performance and public reporting of quality scores: a national survey. Health Aff (Millwood) 2007 1.71
17 Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007 1.69
18 Promotion of prescription drugs to consumers and providers, 2001-2010. PLoS One 2013 1.66
19 Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens 2008 1.60
20 Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 2008 1.58
21 Critical care physicians' approaches to negotiating with surrogate decision makers: a qualitative study. Crit Care Med 2012 1.54
22 Surgeons expect patients to buy-in to postoperative life support preoperatively: results of a national survey. Crit Care Med 2013 1.53
23 Surgeon-reported conflict with intensivists about postoperative goals of care. JAMA Surg 2013 1.49
24 Responding to an FDA warning--geographic variation in the use of rosiglitazone. N Engl J Med 2010 1.46
25 Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care 2010 1.46
26 Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiol Drug Saf 2014 1.42
27 Impact of a drug utilization review program on high-risk use of prescription controlled substances. Pharmacoepidemiol Drug Saf 2013 1.42
28 Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care 2013 1.40
29 Should editorials in peer-reviewed journals be signed? Chest 2006 1.40
30 Recommendations to limit life support: a national survey of critical care physicians. Am J Respir Crit Care Med 2012 1.39
31 Prescriptions, nonmedical use, and emergency department visits involving prescription stimulants. J Clin Psychiatry 2016 1.39
32 National trends in ambulatory asthma treatment, 1997-2009. J Gen Intern Med 2011 1.37
33 U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf 2009 1.34
34 Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care 2013 1.32
35 Elderly patients' preferences and experiences with providers in managing their drug costs. J Am Geriatr Soc 2007 1.21
36 Impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Serv Res 2009 1.19
37 Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. Pharmacoepidemiol Drug Saf 2010 1.19
38 Physicians' experience with surrogate decision making for hospitalized adults. J Gen Intern Med 2009 1.15
39 Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. Acad Pediatr 2012 1.15
40 Physician consideration of patients' out-of-pocket costs in making common clinical decisions. Arch Intern Med 2007 1.11
41 The impact of the Medicare Part D prescription benefit on generic drug use. J Gen Intern Med 2008 1.08
42 Rethinking the ethical framework for surrogate decision making: a qualitative study of physicians. J Clin Ethics 2008 1.03
43 The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Serv Res 2011 0.98
44 National prevalence of lifestyle counseling or referral among African-Americans and whites with diabetes. J Gen Intern Med 2008 0.94
45 Assessing competence of residents to discuss end-of-life issues. J Palliat Med 2005 0.93
46 Mind the gap: understanding the effects of pharmaceutical direct-to-consumer advertising. Med Care 2014 0.93
47 Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Res Treat 2012 0.92
48 A qualitative exploration of depression in emerging adulthood: disorder, development, and social context. Gen Hosp Psychiatry 2007 0.92
49 Should our well-child care system be redesigned? A national survey of pediatricians. Pediatrics 2006 0.92
50 Physicians' views on the importance of patient preferences in surrogate decision-making. J Am Geriatr Soc 2010 0.92
51 Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 2015 0.91
52 Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiol Drug Saf 2012 0.89
53 Health plan utilization and costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm 2013 0.89
54 State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. Health Aff (Millwood) 2012 0.88
55 Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. Psychiatr Serv 2013 0.86
56 Design and evaluation of a workplace intervention to promote organ donation. Prog Transplant 2006 0.86
57 Influence of patient race on physician prescribing decisions: a randomized on-line experiment. J Gen Intern Med 2009 0.85
58 The "Hassle Factor": what motivates physicians to manipulate reimbursement rules? Arch Intern Med 2002 0.84
59 Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. JAMA 2011 0.84
60 The association between family structure, reports of illness and health care demand for children: evidence from rural Bangladesh. J Biosoc Sci 2009 0.84
61 A qualitative study of physicians' engagement in reducing healthcare disparities. J Natl Med Assoc 2007 0.83
62 Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009. Psychiatr Serv 2012 0.83
63 Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. Am J Addict 2015 0.83
64 Turning and churning: loss of health insurance among adults in Medicaid. J Gen Intern Med 2009 0.83
65 Primary Care Physicians' Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion. Clin J Pain 2016 0.82
66 Unsupported off-label use of cancer therapies: new challenges in the era of biopharmaceuticals. Expert Rev Pharmacoecon Outcomes Res 2011 0.82
67 Effect of physician payment disclosure laws on prescribing. Arch Intern Med 2012 0.80
68 Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res 2012 0.79
69 Is treatment heterogeneity an Achilles' heel for comparative effectiveness research? Pharmacotherapy 2012 0.79
70 Construct validity and factor structure of survey-based assessment of cost-related medication burden. Med Care 2015 0.79
71 Importance of distinguishing supported and unsupported off-label drug use. Arch Intern Med 2010 0.79
72 New technologies meeting old professional boundaries: the emergence of carotid artery stenting. J Am Coll Surg 2005 0.78
73 Clinical prescribing (and off-label use) in a second-best world. Med Care 2010 0.78
74 A practical physicians' guide to the Medicare drug benefit plan. Mayo Clin Proc 2006 0.78
75 Association between unemployment rates and prescription drug utilization in the United States, 2007-2010. BMC Health Serv Res 2012 0.78
76 Health information technology and physicians' knowledge of drug costs. Am J Manag Care 2010 0.78
77 Primary care physicians' views of Medicare Part D. Am J Manag Care 2008 0.78
78 Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use. PM R 2013 0.77
79 Physician financial incentives and care for the underserved in the United States. Am J Manag Care 2014 0.77
80 Screening and treatment of hypercholesterolemia for prevention of coronary heart disease. Manag Care Interface 2006 0.77
81 Academic medical centers and underserved communities: modern complexities of an enduring relationship. J Natl Med Assoc 2010 0.77
82 Impact of family structure on stimulant use among children with attention-deficit/hyperactivity disorder. Health Serv Res 2009 0.76
83 Disposing of medicines safely. Am J Public Health 2014 0.76
84 Impact of out-of-pocket spending caps on financial burden of those with group health insurance. J Gen Intern Med 2014 0.75
85 Drug postmarketing studies--reply. JAMA 2013 0.75
86 Shoring up professionalism. Building on disagreements between residents and attending physicians. Can Fam Physician 2006 0.75
87 Cost containment and patient well-being. J Gen Intern Med 2015 0.75
88 Just because it's low cost doesn't mean it's accessible. J Gen Intern Med 2012 0.75
89 Academic centers play a vital role in the study of drug safety and effectiveness. Clin Ther 2013 0.75
90 Reply letter: are FDA prescription drug safety plans working? A case study of isotretinoin. Pharmacoepidemiol Drug Saf 2014 0.75
91 Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia. Psychiatr Serv 2013 0.75
92 The nuances of self-disclosure. Arch Intern Med 2008 0.75
93 From the editors' desk: The July effect. J Gen Intern Med 2011 0.75
94 Exploring patient preferences for infrainguinal bypass operation. J Am Coll Surg 2006 0.75
95 Brief report: do patients with poor outcomes regret having had infrainguinal bypass surgery? J Surg Res 2007 0.75
96 A comparison of patient and physician beliefs about infrainguinal bypass operation: what role should surgical optimism play? Surgery 2006 0.75
97 Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. Am J Addict 2014 0.75
98 Effect of Direct-to-Consumer Advertising (DTCA) on Statin Use in the United States. Med Care 2017 0.75
99 Can healers have private lives? Virtual Mentor 2006 0.75
100 Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Int J Risk Saf Med 2012 0.75
101 Cost savings associated with filling a 3-month supply of prescription medicines. Appl Health Econ Health Policy 2009 0.75
102 Lack of effect of guideline changes on LDL cholesterol reporting and control for diabetes visits in the U.S., 1995-2004. Diabetes Care 2005 0.75
103 Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation. J Manag Care Spec Pharm 2015 0.75
104 Evaluating the Impact of Prescription Fill Rates on Risk Stratification Model Performance. Med Care 2017 0.75
105 Association between the commercial characteristics of psychotropic drugs and their off-label use. Med Care 2012 0.75